Internal Medicine Center Concludes Research to Benefit Diabetics – A new drug that could significantly reduce the risk of cardiovascular events
MOBILE, AL- Internal Medicine Center announced today its participation in a LEADER clinical research trial investigating the cardiovascular safety of Victoza® (liraglutide [rDNA origin] injection) over a period of up to 5 years in more than 9,000 adult patients with type 2 diabetes at high risk of major adverse cardiovascular events. Patients were given either Victoza® or placebo to their standard of care and met the primary endpoint of showing non-inferiority as well as demonstrated superiority, with a statistically significant reduction in cardiovascular risk. The overall goal of the study was defined as the composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. This drug demonstrated a significant reduction of major adverse cardiovascular events.
“We were very excited to be a part of this study, especially since in the US we continue to see an alarming increase in the prevalence of obesity, diabetes, and cardiovascular disease. Results of this study will be presented at the 76th Scientific Sessions of the American Diabetes Association in June in New Orleans. We can’t wait to share more information about this study this summer,” Robyn Simons, RN, MA, CCRC, Clinical Research Director, Internal Medicine Center.
For more information on Internal Medicine’s Clinical Research Division and current studies contact Robyn Simons, RN at rsimons@internalmedicinecenter.org, 251.414.5900 and Vicki Wren, RN at vwren@internalmedicinecenter.org, 251-410-3081or visit www.InternalMedicineCenter.org.
About LEADER
LEADER was a multicenter, international, randomized, double-blind, placebo-controlled trial investigating the long-term effects of Victoza® (1.2 and 1.8 mg) compared to placebo, both in addition to standard of care, in adults with type 2 diabetes at high risk of cardiovascular events. The trial was initiated in September 2010 and randomized 9,340 people with type 2 diabetes from 32 countries who were followed for 3.5–5 years. The primary endpoint was the first occurrence of a composite cardiovascular outcome comprising cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.
About Victoza®
Victoza® is a human glucagon-like peptide-1 (GLP-1) analog that was approved by the U.S. Food and Drug Administration on January 25, 2010, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
As of March 2015, Victoza® has been commercially launched in 75 countries, including the United States, Canada, Japan, United Kingdom, Germany, France, Italy, Denmark, Hungary, Russia India, Brazil, Mexico, Argentina, Malaysia and China.
About Diabetes
According to the Centers for Disease Control (CDC), more than 29 million people in the United States are affected by diabetes. Type 2 diabetes accounts for 90 to 95 percent of all diabetes cases. Diabetes is emerging as one of the most serious health problems of our time; the number of Americans with diabetes has almost quadrupled over the past 30 years.
About Internal Medicine Center
Internal Medicine Center, LLC is a multi-specialty clinic providing quality care in a compassionate environment since 1946. As the largest independent multi-specialty clinic in Mobile, we take pride in creating an environment where our physicians can provide individualized, quality care to our patients. For more information about IMC services and providers go to www.InternalMedicineCenter.org or call 251.414.5900.
